Malgorzata Bobrowicz

List of Publications by Year
in descending order

24 papers	360 citations	840776 11 h-index	839539 18 g-index
24 all docs	24 docs citations	24 times ranked	735 citing authors

#	Article	IF	Citations
1	Molecular Aspects of Resistance to Immunotherapiesâ€”Advances in Understanding and Management of Diffuse Large B-Cell Lymphoma. International Journal of Molecular Sciences, 2022, 23, 1501.	4.1	13
2	The â€œMagic Bulletâ€•Is Here? Cell-Based Immunotherapies for Hematological Malignancies in the Twilight of the Chemotherapy Era. Cells, 2021, 10, 1511.	4.1	3
3	Enhancement of antibody-dependent cellular cytotoxicity is associated with treatment response to extracorporeal photopheresis in SÃ©zary syndrome. OncoImmunology, 2021, 10, 1873530.	4.6	6
4	Pathogenesis and Therapy of Primary Cutaneous T-Cell Lymphoma: Collegium Internationale Allergologicum (CIA) Update 2020. International Archives of Allergy and Immunology, 2020, 181, 733-745.	2.1	35
5	CD37 in B Cell Derived Tumorsâ€”More than Just a Docking Point for Monoclonal Antibodies. International Journal of Molecular Sciences, 2020, 21, 9531.	4.1	16
6	Blockade of programmed cell death protein 1 (PD-1) in SÃ©zary syndrome reduces Th2 phenotype of non-tumoral T lymphocytes but may enhance tumor proliferation. OncoImmunology, 2020, 9, 1738797.	4.6	32
7	Selective inhibition of HDAC6 sensitizes cutaneous Tâ€˜cell lymphoma to PI3K inhibitors. Oncology Letters, 2020, 20, 533-540.	1.8	6
8	Monoclonal Antibodies in Dermatooncologyâ€”State of the Art and Future Perspectives. Cancers, 2019, 11, 1420.	3.7	9
9	Divergent LAG-3 versus BTLA, TIGIT, and FCRL3 expression in SÃ©zary syndrome. Leukemia and Lymphoma, 2019, 60, 1899-1907.	1.3	23
10	Inhibition of thioredoxin-dependent H2O2 removal sensitizes malignant B-cells to pharmacological ascorbate. Redox Biology, 2019, 21, 101062.	9.0	29
11	FOXO1 promotes resistance of non-Hodgkin lymphomas to anti-CD20-based therapy. OncoImmunology, 2018, 7, e1423183.	4.6	23
12	Typical and Atypical Inducers of Lysosomal Cell Death: A Promising Anticancer Strategy. International Journal of Molecular Sciences, 2018, 19, 2256.	4.1	63
13	SHP1 Deficiency Is Responsible for the Constitutive Activation of the BCR Pathway in GCB DLBCL. Blood, 2018, 132, 2860-2860.	1.4	2
14	HDAC6 inhibition upregulates CD20 levels and increases the efficacy of anti-CD20 monoclonal antibodies. Blood, 2017, 130, 1628-1638.	1.4	40
15	Lysosomal Disruption Augments Obinutuzumab-Induced Direct Cell Death. Blood, 2016, 128, 2766-2766.	1.4	3
16	HDAC6 Inhibition Increases Translation of CD20 mRNA and Potentiates the Efficacy of Anti-CD20 Immunotherapy. Blood, 2016, 128, 1586-1586.	1.4	0
17	Adenanthin, a new inhibitor of thiolâ€dependent antioxidant enzymes, impairs the effector functions of human natural killer cells. Immunology, 2015, 146, 173-183.	4.4	16
18	B-cell receptor signaling in the pathogenesis of lymphoid malignancies. Blood Cells, Molecules, and Diseases, 2015, 55, 255-265.	1.4	22

#	Article	IF	Citations
19	Inhibitors of SRC kinases impair antitumor activity of anti-CD20 monoclonal antibodies. MAbs, 2014, 6, 1300-1313.	5.2	16
20	HDAC Inhibitors As Potential New Agents Improving the Efficacy of Monoclonal Antibodies. Blood, 2014, 124, 3641-3641.	1.4	0
21	Influence of Btk Inhibitors on Antitumor Activity of Natural Killer Cells. Blood, 2014, 124, 2742-2742.	1.4	1
22	Inhibitors Of Src Family and AKT Regulate The Activity Of CD20 Promoter. Blood, 2013, 122, 1838-1838.	1.4	1
23	HDAC6 Inhibition Increases CD20 Level and Improves The Efficacy Of Anti-CD20 Monoclonal Antibodies. Blood, 2013, 122, 4406-4406.	1.4	1
24	Inhibitors Of B-Cell Receptor Molecules Affect Surface CD20 and Impair Antitumor Activity Of Anti-CD20 Monoclonal Antibodies. Blood, 2013, 122, 4217-4217.	1.4	0